DSPE-PEG2000-T7

DSPE-PEG2000-T7 is a PEGylated compound composed of DSPE and peptideT7. T7 (HAIYPRH) specifically binds to TfR. DSPE-PEG2000-T7 can be used to prepare T7-modified liposomes, where liposomes modified with both T7 and DA7R peptides can effectively co-deliver Doxorubicin and Vincristine to gliomas. DSPE-PEG2000-T7 can also be used to prepare nanomodulators that mediate the co-delivery of tyrosine hydroxylase mRNA and interferon gene stimulator antagonists for synergistic intervention in Parkinson's disease ^{[1] [2] [3]}.

In Vitro, DSPE-PEG2000-T7 is a PEGylated compound composed of DSPE and the transferrin receptor (TfR) peptide (T7). T7 (HAIYPRH) specifically binds to TfR^[1]. DSPE-PEG2000-T7 can be used to prepare nanomodulators that mediate the co-delivery of tyrosine hydroxylase mRNA and interferon gene stimulator antagonists for synergistic intervention in Parkinson's disease^[2]. DSPE-PEG2000-T7 can be used to prepare T7-modified liposomes, where liposomes modified with both T7 and DA7R peptides can effectively co-deliver Doxorubicin and Vincristine to gliomas^[3].

References:
[1]. Kuang Y, et al. T7 peptide-functionalized nanoparticles utilizing RNA interference for glioma dual targeting. Int J Pharm. 2013 Sep 15;454(1):11-20.
[2]. Yang L, et al. Biomimetic Nanoregulators Mediated Tyrosine Hydroxylase mRNA and Stimulator of Interferon Genes Antagonist Codelivery for Synergistic Therapy on Parkinson's Disease. ACS Nano. 2025 Sep 30;19(38):33734-33748.
[3]. Zhang Y, et al. Dual-modified liposome codelivery of doxorubicin and vincristine improve targeting and therapeutic efficacy of glioma. Drug Deliv. 2017 Nov;24(1):1045-1055.